| |
|
|
|
3 Feb 15 |
Unit 2: Evidence Generation Comparative Effectiveness Trials and Other Prospective Comparative Effectiveness Studies Integrating Genetic Information into Clinical Effectiveness Trials |
David M. Kent, MD, MSc Thomas A. Trikalinos, MD, PhD
|
114 West |
4 Feb 22 |
Personalized Medicine, Heterogeneity of Treatment Effect and Implications for Comparative Effectiveness |
David M. Kent, MD, MSc |
114 West |
5 March 1 |
Retrospective and Observational Comparative Effectiveness Studies |
Dana Gelb Safran, ScD Peter K. Lindenauer, MD, MSc |
First Floor Lecture Hall |
| |
|
|
|
6 March 8 |
Unit 3: Evidence Synthesis Systematic Review and Meta-Analysis |
Joseph Lau, MD Christopher H. Schmid, PhD |
114 West |
| |
|
|
|
7 March 15 |
Unit 4: Evidence Integration Decision modeling - Cost Effectiveness |
John B. Wong, MD Stephen G. Pauker, MD |
812 |
8 March 22 |
Decision modeling - Simulations |
Joshua T. Cohen, PhD |
114 West |
| |
|
|
|
9 March 29 |
Unit 5: Use of Evidence in Decision Making Community Engagement and Input into CER |
Laurel K. Leslie, MD, MPH |
114 West |
10 April 5 |
Clinical Practice Guidelines |
Katrin Uhlig, MD, MS |
114 West |
11 April 12 |
Clinical Effectiveness Trials and Predictive Instruments as Decision Support for Implementing CER |
Harry P. Selker, MD, MSPH |
216 A |
| April 19 |
No Class |
|
|
12 April 26 |
Drug Development in the CER Era |
Kenneth I. Kaitin, PhD |
516 |
13 May 3 |
Using Comparative Effectiveness Research to Reach Employers and Employees |
Debra J. Lerner, MS, PhD |
114 West |
14 May 10 |
Economic and Policy Implications of CER |
Christopher P. Tompkins, PhD |
114 West |
| |
|
|
|
15 May 17 |
Unit 6: Future Directions in CER The IOM 100 Priorities and AHRQ 14 Priority Conditions and Populations |
Thomas W. Concannon, PhD and Faculty panel |
114 West |